
Aardvark released exploratory data from its stopped Phase 3 HERO trial in Prader-Willi syndrome after FDA lifted the hold, and plans a redesigned Phase 3.
Catalent Pharma Solutions announced that it is investing $5.5 million at its 200,000+ square foot Philadelphia, Pennsylvania site to provide additional clinical packaging and storage capacity. This provider of technologies and development solutions for drugs, biologics and consumer health products is looking to expand their Philadelphia location with many different advances.
Read the full release






